Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 17Myeloid 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 1Monoclonal Gammopathy of Undetermined Significance 1Hematologic Neoplasms 1Anemia, Aplastic 1

Interventions

fludarabine 10Cyclophosphamide 8fludarabine phosphate 7Whole-Body Irradiation 7Tacrolimus 5Mycophenolic Acid 5Melphalan 5Thiotepa 4Peripheral Blood Stem Cell Transplantation 4Busulfan 4AP 1903 reagent 4thymoglobulin 3Sirolimus 3Cord Blood Stem Cell Transplantation 3Alemtuzumab 3Stem Cell Transplantation 2Specimen Handling 2Rituximab 2Platelet Transfusion 2Meropenem 2Cyclosporine 2Biopsy 2Antilymphocyte Serum 2visilizumab 1venetoclax 1trametinib 1ruxolitinib 1regorafenib 1ponatinib 1pertuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hematologic Neoplasms × Practice Guidelines as Topic × Classical hematology × Clear all
NCT04439006 2023-12-26

Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization

Ohio State University Comprehensive Cancer Center

Phase 1 Completed
10 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Aplastic, Monoclonal Gammopathy of Undetermined Significance, Myelodysplastic Syndromes, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡